Elevated Serum Inhibin Concentrations in Postmenopausal Women With Ovarian Tumors

Healy, David; Burger, Henry; Mamers, Pamela; Jobling, Tom; Bangah, Mohan; Quinn, Michael; Grant, Peter; Day, Arthur J.; Rome, Robert M.; Campbell, James J.

doi:10.1097/00006254-199404000-00022

Cited by 54 publications

(86 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…15 In the present study, combined CA125 and serum Inhibin was found to be raised in 70% of benign and 100% of malignant cases. Sensitivity of combined assay was 100% for detection of carcinoma ovary and specificity was 30%.…”

Section: Discussionsupporting

confidence: 53%

Combined use of CA 125 and Inhibin as tumor marker for detection of ovarian cancer in comparison to CA 125 or Inhibin alone

Dubbewar¹,

Pathak²,

Biswas³

et al. 2017

Int J Reprod Contracept Obstet Gynecol

View full text Add to dashboard Cite

Background: Ovarian cancers are diagnosed at an advanced stage. Early diagnosis is the key to reduce death from ovarian cancer. The present study is an effort to assess the suitability of combined test using CA 125 and Inhibin for early diagnosis of ovarian cancer as compared to CA125 or Inhibin alone.Methods: Fifty women with clinical suspicion of ovarian malignancy attending Gynae OPD were enrolled. All of these women were subjected to estimation of CA 125 and Inhibin levels prior to surgical intervention. A value of 35 IU/ml was taken as positive for CA 125. For Inhibin, 10.5 pg/ml was taken as cut off for premenopausal patients, whereas, any detectable assays were taken as positive for postmenopausal patients. The results were analyzed after establishing final histopathology of the disease.Results: Out of 50 patients recruited, 30 (60%) were found to have carcinoma ovary and 20 (40%) were found to have benign diseases. Out of 30 cases of carcinoma ovary, CA125 was raised in 81% of cases and Inhibin was raised in 78% of cases. For detection of carcinoma ovary, CA 125 was found to have a sensitivity of 90% and specificity of 60% with a positive predictive value of 77% and negative predictive value of 80% which were statistically significant. Sensitivity and specificity of serum Inhibin for the same was 86.6% and 20% respectively. The positive and negative predictive value were 61.9% and 50%, which were not statistically significant. Sensitivity and specificity of combined CA125 and Inhibin were 100% and 30% respectively. The positive and negative predictive value were 68.1% and 100% respectively, which were statistically significant.Conclusions: Combined use of CA125 and Inhibin has got better sensitivity and specificity in detection of ovarian cancer in comparison to CA 125 or Inhibin used alone.

show abstract

Section: Discussionsupporting

confidence: 53%

Combined use of CA 125 and Inhibin as tumor marker for detection of ovarian cancer in comparison to CA 125 or Inhibin alone

Dubbewar¹,

Pathak²,

Biswas³

et al. 2017

Int J Reprod Contracept Obstet Gynecol

View full text Add to dashboard Cite

show abstract

“…16,17 Most common tumour markers useful in early detection of recurrence are inhibin B and Mullerian inhibiting substance/AMH. [18][19][20] …”

Section: Discussion Of Managementmentioning

confidence: 99%

Huge Twisted and Ruptured Granulosa Cell Tumour in a Perimenopausal Female With Haemorrhagic Shock - A Case Report

Kautish¹

2018

jebmh

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“…Elevated serum inhibin levels have been noted in postmenopausal women with ovarian tumours (Healy et al, 1993) and it has been suggested that inhibin may have a role as a tumour marker, particularly when used in combination with CA125 (Robertson et al, 1999). Elevated serum inhibin and pro-alpha C levels have been reported in patients with GCTs and mucinous tumours of the ovary (Healy et al, 1993;Jobling et al, 1994;Boggess et al, 1997). Serum inhibin has never been evaluated as a marker for response to treatment in epithelial ovarian cancer although a small series has evaluated it in monitoring response to Tamoxifen and goserelin in ovarian cancer J Hasan et al GnRH analogues in GCT (Kauppila et al, 1992).…”

Section: Discussionmentioning

confidence: 99%

Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancer

et al. 2005

View full text Add to dashboard Cite

Endocrine therapy is a recognised option in the treatment of chemo-resistant ovarian cancer. We conducted a nonrandomised phase II evaluation of combination endocrine therapy with tamoxifen and goserelin in patients with advanced ovarian cancer that had recurred following chemotherapy. In total, 26 patients entered the study, of which 17 had platinum-resistant disease. The median age was 63 years and enrolled patients had received a median of three chemotherapy regimens prior to trial entry. Patients were given oral tamoxifen 20 mg twice daily on a continuous basis and subcutaneous goserelin 3.6 mg once a month until disease progression. Using the definition of endocrine response that included patients with stable disease (SD) of 6 months or greater, the overall response rate (clinical benefit rate) was 50%. This included one complete response (CR) (3.8%), two partial responses (PR) (7.7%) and 10 patients with SD (38.5%). The median progression-free interval (PFI) was 4 months (95% CI 2.4 -9.6) while the median overall survival (OS) was 13.6 months (95% CI 5.5 -30.6). Four patients received treatment for more than 2 years (range 1 -31) and one of them is still on treatment. In none of the four patients was there any evidence of recurrent or cumulative treatment related toxicity. Treatment-limiting toxicity was not seen in any of the study population. Endocrine data demonstrated a marked suppression of luteinising hormone (LH) and follicle-stimulating hormone (FSH) to less than 4% of baseline values. No consistent correlation could be established between LH/FSH suppression and tumour response. Likewise no relationship was observed between Inhibin A/B and pro-alpha C levels and tumour response. Inhibin is unlikely to be a useful surrogate marker for response in locally advanced or metastatic ovarian cancer. Combination endocrine therapy with tamoxifen and goserelin is an active regimen in platinum-resistant ovarian cancer patients. Hormonal therapy is advantageous in its relative lack of toxicity, ease of administration and tolerability, thus making it suitable for patients with heavily pretreated disease, compromised bone marrow function and other comorbid conditions that contraindicate cytotoxic therapy as well as in patients with indolent disease.

show abstract

Elevated Serum Inhibin Concentrations in Postmenopausal Women With Ovarian Tumors

Cited by 54 publications

References 0 publications

Combined use of CA 125 and Inhibin as tumor marker for detection of ovarian cancer in comparison to CA 125 or Inhibin alone

Combined use of CA 125 and Inhibin as tumor marker for detection of ovarian cancer in comparison to CA 125 or Inhibin alone

Huge Twisted and Ruptured Granulosa Cell Tumour in a Perimenopausal Female With Haemorrhagic Shock - A Case Report

Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancer

Contact Info

Product

Resources

About